In Vitro, Ex Vivo, and In Vivo Evidence of Nitrate-Reducing Activity in Levilactobacillus brevis CD2: A Potential Tool for Oral and Systemic Health Applications DOI Creative Commons
Serena Altamura, Francesca Rosaria Augello, Francesca Lombardi

et al.

Foods, Journal Year: 2025, Volume and Issue: 14(9), P. 1512 - 1512

Published: April 26, 2025

Growing evidence supports the use of nitrate-reducing bacterial strains as probiotics to enhance benefits nitrate metabolism for both oral and systemic health. This study aimed test reductase activity Levilactobacillus brevis CD2 (DSM-27961/CNCM I-5566), a strain widely used starter culture in fermented foods recognized its multifaceted health-promoting probiotic properties. We also sought determine whether lysate enhances reduction ex vivo using six salivary samples from healthy subjects while evaluating potential influence on pH buffering capacity. Considering established link between lactate nitrite production, we assessed levels D-lactate after 3-hour incubation with or without Lv. brevis. The results indicate that exhibits significant intrinsic concentration-dependent activity. Additionally, treatment 3 h significantly increased generation across all saliva samples, further enhancement observed addition exogenous nitrates. improved capacity, particularly when combined nitrate. Furthermore, resulted reduced D-lactate. To support validate our vitro findings, evaluated individuals treated four weeks lozenges. Of note, indicated group showed increase capacity compared baseline placebo treatment. Overall, suggests acts probiotic, providing new insights into health complementing findings previous studies.

Language: Английский

Levilactobacillus brevis CD2 as a multifaceted probiotic to preserve oral health: results of a double-blind, randomized, placebo-controlled trial in healthy adults DOI Creative Commons
Serena Altamura, Francesca Lombardi, Francesca Rosaria Augello

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 28, 2025

A growing number of in vitro and vivo studies suggest the application probiotics as a natural approach to maintaining oral health. This double-blind, randomized controlled trial aimed evaluate efficacy Levilactobacillus brevis CD2 (CNCM I-5566), multifunctional probiotic frequently used medicine, preserving or improving several recognized health indicators. Thirty consenting healthy adults were receive four lozenges per day L. (n = 15) placebo over weeks. Clinical parameters (full-mouth bleeding on probing (BoP) plaque index (PI) scores) recorded. Unstimulated saliva was collected measure salivation rate, pH, buffer capacity. Salivary biomarkers analyzed, including glucose, D-lactate, secretory immunoglobulins (sIgA). salivary assessed at baseline, after weeks intervention, two post-intervention. Wilcoxon rank-sum test robust regression analysis for statistical comparisons. The possible mediating effect PI BoP changes assessed. After weeks, group showed significant improvements compared baseline placebo. had higher rate than treatment washout. While pH not significant, buffering capacity increased glucose D-lactate levels lower post-treatment sIgA values remained stable washout group. No adverse effects reported. with significantly improved clinical parameters, supporting its ClinicalTrials.gov , NCT06457724; Registered 7 June 2024 - Retrospectively registered; https://clinicaltrials.gov/study/NCT06457724?viewType=Table&page=452&rank=4512#study-overview .

Language: Английский

Citations

0
In Vitro, Ex Vivo, and In Vivo Evidence of Nitrate-Reducing Activity in Levilactobacillus brevis CD2: A Potential Tool for Oral and Systemic Health Applications DOI Creative Commons
Serena Altamura, Francesca Rosaria Augello, Francesca Lombardi

et al.

Foods, Journal Year: 2025, Volume and Issue: 14(9), P. 1512 - 1512

Published: April 26, 2025

Growing evidence supports the use of nitrate-reducing bacterial strains as probiotics to enhance benefits nitrate metabolism for both oral and systemic health. This study aimed test reductase activity Levilactobacillus brevis CD2 (DSM-27961/CNCM I-5566), a strain widely used starter culture in fermented foods recognized its multifaceted health-promoting probiotic properties. We also sought determine whether lysate enhances reduction ex vivo using six salivary samples from healthy subjects while evaluating potential influence on pH buffering capacity. Considering established link between lactate nitrite production, we assessed levels D-lactate after 3-hour incubation with or without Lv. brevis. The results indicate that exhibits significant intrinsic concentration-dependent activity. Additionally, treatment 3 h significantly increased generation across all saliva samples, further enhancement observed addition exogenous nitrates. improved capacity, particularly when combined nitrate. Furthermore, resulted reduced D-lactate. To support validate our vitro findings, evaluated individuals treated four weeks lozenges. Of note, indicated group showed increase capacity compared baseline placebo treatment. Overall, suggests acts probiotic, providing new insights into health complementing findings previous studies.

Language: Английский

Citations

0